Contemporary American and European Guidelines for Heart Failure Management

This review serves to compare contemporary clinical practice recommendations for the management of heart failure (HF), as codi fied in the 2021 European Society of Cardiology (ESC) guideline, the 2022 American College of Cardiology (ACC)/ American Heart Association (AHA)/Heart Failure Society of America (HFSA) guideline, and the 2023 focused update of the 2021 ESC document. Overall, these guidelines aim to solidify signi ficant advances throughout the HF continuum since the publication of previous full guideline iterations (2013 and 2016 for the ACC/AHA and ESC, respectively). All guidelines provide new recommendations for an increasingly complex landscape of HF care, with focus on primary HF prevention, HF stages, rapid initiation and optimization of evidence-based pharmacotherapies, overlapping cardiac and noncardiac comorbidities, device-based therapies, and management pathways for special groups of patients, including those with cardiac amyloidosis. Importantly, the ACC/AHA/HFSA document features special emphasis on HF risk prediction and screening, cost/value, social determinants of health, and health care disparities. The review discusses major similarities and differences between these recent guidelines and guideline updates, as well as their potential downstream implications for clinical care. (J Am Coll Cardiol HF 2024;12:810 -825) (c) 2024 by the American College of Cardiology Foundation.